Sentences with phrase «many disease»

«Beyond giving us so much data to explore,» said Perlis, «being able to show that depression is a brain disease, that there is biology associated with it, I think that's really critical for people to understand.»

«It's a disease transmitted through sex, but certainly at this point we wouldn't carry it to say it's a sexually transmitted disease,» Dr. Robert Segal told Business Insider during a Facebook Live session.

• Mereo BioPharma, a London - based rare disease drug firm, filed an IPO of up to $ 81 million.

And in the long run, workplace stress has been linked to everything from metabolic syndrome to cardiovascular disease.

Cornell's mother suffered from heart disease through much of her life, and the two of them lived very modestly off her disability check in working - class White - stone, Queens.

Meanwhile, about half of all Americans have at least one chronic disease, which is accounting for 80 % of the healthcare costs.

Streicher agrees, noting that the IUD's entire anatomy has been revised (they used to look like this), and that modern IUDs do not increase the chance of contracting a pelvic inflammatory disease.

During the session, a trio of experts discussed the opportunities and challenges of a more globalized world, including cross-border clinical trials, the spread of disease and emerging pathogens and managing supply chains.

And the company hopes the system can drastically improve the «diagnostic journeys» that those with rare diseases typically face: Such patients, on average, are seen by seven doctors before the correct diagnosis is made.

The world is suffering a disease.

Novartis, Amgen, and BAI are trying to figure out whether or not an experimental treatment called CNP520 can delay Alzheimer's in the people at high risk for the disease — or prevent it altogether.

About 69 million employees in the U.S. say they miss work because of health problems every year, which reduces economic output by $ 260 billion per year, according to the Centers for Disease Control and Prevention.

Otonomy is also testing a steroid gel to treat Ménière's disease, which causes debilitating vertigo, tinnitus, and hearing loss.

Made by companies like Gilead, AbbVie, Merck, and others, drugs that treat the disease are listed at tens of thousands of dollars in the U.S..

But as the good doctor tells Fortune's Erika Fry, there is another infectious disease that's even more dangerous to humanity — and that's the «failure of imagination.»

CTE (chronic traumatic encephalopathy, a progressive degenerative disease caused by a severe blow or repeated blows to the head) can result from impacts that don't even reach the concussion level.

Heart disease is the leading cause of death for men and women in the U.S. Every year over 700,000 Americans have a heart attack and half of those are fatal.

What's more troubling is that the drugs, unlike statins and other common heart disease medications, don't have a whole lot of alternatives.

To try and stop the spread of disease, scientists have started looking into how to quell mosquito populations.

The changing of the food chain around the world has dramatically changed the onset of diseases.»

Viome claims that with proper diet and nutrition, people can fight off the chronic diseases to which they're most susceptible.

This way, patients with chronic diseases like hypertension and diabetes (and their physicians) can figure out the most effective dosing regimens.

Color announced Thursday that it's introducing a Hereditary High Cholesterol Test that can detect a genetic mutation indicating Familial Hypercholesterolemia (FH), a genetic disorder which leaves carriers with high cholesterol that often leads to early heart disease.

Although her struggle with the incurable disease has been long and difficult, Dunham said she has a newfound agency and determination to be a mother.

When those are damaged — by disease, injury, or aging — hearing loss can occur, and until now that was typically viewed as irreversible.

Like in 1989, when, two months after her husband's inauguration, she visited a residential home for babies infected with AIDS and publicly kissed a child and hugged an adult diagnosed with HIV, defying the conventional wisdom at the time that the disease was contagious.

Lifestyle changes following a disease diagnosis have led a Perth woman to an unexpected business success.

«We're in a serious jam,» says Gerry Wright, director of the Michael DeGroote Institute for Infectious Disease Research at McMaster University.

«The potion is not a panacea — it does not have a magic power against all diseases,» said a researcher experienced in cockroach - related medicines at the Institute of Materia Medica at the Chinese Academy of Medical Sciences (CAMS) in Beijing.

The Alphabet - backed Silicon Valley startup, valued at $ 1.1 billion, became the first company allowed to sell genetic tests (and accompanying health - risk reports) for 10 different diseases directly to consumers without a prescription.

With a sturdy, adjustable - height tabletop and a range of 0.6 to 6.5 kilometres per hour, I would soon be typing and talking without worrying about the «sitting disease» epidemic that's killing North Americans.

It is not yet known whether his disease is related to his death, although CBC is reporting that he may have died of a heart attack.

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

You have said that when grunge hit, it was like being a doctor specializing in a disease they just found a cure for.

Tehrani targeted the most conservative companies in the business, ones that had no presence in a particular class of disease targets, to entice those who might jump on the bandwagon later.

The PGS platform promised genetic risk reports for more than 250 disease at the time — but, after the FDA smackdown, 23andMe was forced to stop marketing the service and pursue a piecemeal strategy of winning regulatory approval of individual tests.

That means that, for the first time ever, Americans won't have to get a prescription to receive plain - English medical reports about their chances of developing diseases like Alzheimer's, Parkinson's disease, celiac disease, and other disorders based on analyses of their genetic makeup.

And in populations where coconut oil is commonly eaten, high cholesterol levels and heart disease are not common.

«The reason I'm here is that I was very excited about the problem that we weren't addressing in pharma — dealing with the 86 million people with pre-diabetes that can lead to a tsunami in health care costs,» he said, adding that «pharma is looking beyond the pill» and that «digital therapeutics will become therapeutics,» particularly when it comes to preventing disease.

Not surprisingly, the spread of diseases (not to mention unhealthy lifestyles that lead to diseases) on a global level is much easier than coordinating care, managing supply chains and clinical trials and rolling out treatments.

Amyotrophic lateral sclerosis, commonly called ALS or Lou Gehrig's disease, is a devastating, degenerative neurological disorder.

«It is our hope that by targeting people earlier, we will have a better chance of delaying or preventing the onset of the disease,» said BAI director Dr. Pierre N. Tariot in a statement.

The Bahamian - American physician and special adviser to the Carter Center is one of the key individuals responsible for the eradication of smallpox — a truly terrifying disease that in the 20th century alone killed as many as 300 million people.

But what if AI and deep learning could help doctors figure out a patient's disease simply by analyzing a face — no scans or testing required?

Omada's digital therapeutics platform attempts to address disparate health care needs that can be particularly cumbersome for people at risk for chronic diseases like diabetes through a combination of data analytics, user engagement, and the broad goal of preventing these kinds of conditions from developing in the first place.

That has both positive and negative implications when it comes to managing disease and care on a global level.

«If, for example, you follow 1,000 people who have a healthy lifestyle and 1,000 who don't,» he says, «without question there will be many more chronic diseases that develop in the 1,000 who don't have a healthy lifestyle.

Highly successful people tend to have the British disease of the stiff upper lip.

The project's launch featured a prominent ALS patient and research advocate: Pat Quinn, co-founder of the ALS Ice Bucket Challenge, an initially - derided social media stunt that went on to raise hundreds of millions of dollars for ALS research and may have spurred important new discoveries about the disease's genetic roots.

Glaxo's rare disease unit.